OFD1 and neoplasm: Across all tumor types, the combination of doxycycline and olaparib showed the most pronounced tumor regression compared to that of the other groups, demonstrating a strong synergistic effect of OFD1 inhibition and PARPi on BRCA-associated tumors (Fig. 8k–p, Supplementary Fig. 10b, c).